Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 26719230

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2016 Apr 2
First author
Zalcman G

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2016 Apr 2;387(10026):1352-1354. doi: 10.1016/S0140-6736(15)01311-2.
    note
    Source null
    related pmid
    26719231
    relationship
    Comment in
  2. citation
    Lancet. 2016 Apr 2;387(10026):e24. doi: 10.1016/S0140-6736(16)30084-8.
    note
    Source null
    related pmid
    27115822
    relationship
    Erratum in
  3. citation
    Am J Respir Crit Care Med. 2017 Aug 1;196(3):382-385. doi: 10.1164/rccm.201608-1676RR.
    note
    Source null
    related pmid
    28598211
    relationship
    Comment in

Authors and identifiers

  1. name
    Zalcman G
    type
    Author
  2. name
    Mazieres J
    type
    Author
  3. name
    Margery J
    type
    Author
  4. name
    Greillier L
    type
    Author
  5. name
    Audigier-Valette C
    type
    Author
  6. name
    Moro-Sibilot D
    type
    Author
  7. name
    Molinier O
    type
    Author
  8. name
    Corre R
    type
    Author
  9. name
    Monnet I
    type
    Author
  10. name
    Gounant V
    type
    Author
  11. name
    Rivière F
    type
    Author
  12. name
    Janicot H
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Zalcman G
    type
    Author
  2. name
    Mazieres J
    type
    Author
  3. name
    Margery J
    type
    Author
  4. name
    Greillier L
    type
    Author
  5. name
    Audigier-Valette C
    type
    Author
  6. name
    Moro-Sibilot D
    type
    Author
  7. name
    Molinier O
    type
    Author
  8. name
    Corre R
    type
    Author
  9. name
    Monnet I
    type
    Author
  10. name
    Gounant V
    type
    Author
  11. name
    Rivière F
    type
    Author
  12. name
    Janicot H
    type
    Author
bibliography ids
  1. nci-bib-5484efea450a488bb48b59eb
book metadata
content sha256
b49e9450d207fa6b84dcdbddf1b5a32e942aeae576bcab6b9d138b08499d5185
document type
citation
dois
  1. 10.1016/S0140-6736(15)01238-6
electronic publication date
display
2015 Dec 21
precision
day
year
2015
evidence scope
bibliographic_metadata_only
id
pubmed:26719230
immutable id
pubmed:26719230@b49e9450d207fa6b84dcdbddf1b5a32e942aeae576bcab6b9d138b08499d5185
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
10026
name
Lancet (London, England)
nlm unique id
2985213R
pages
1405-1414
volume
387
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2016 Apr 2;387(10026):1352-1354. doi: 10.1016/S0140-6736(15)01311-2.
    note
    Source null
    related pmid
    26719231
    relationship
    Comment in
  2. citation
    Lancet. 2016 Apr 2;387(10026):e24. doi: 10.1016/S0140-6736(16)30084-8.
    note
    Source null
    related pmid
    27115822
    relationship
    Erratum in
  3. citation
    Am J Respir Crit Care Med. 2017 Aug 1;196(3):382-385. doi: 10.1164/rccm.201608-1676RR.
    note
    Source null
    related pmid
    28598211
    relationship
    Comment in
outcomes validated
false
pmid
26719230
provenance
batch id
948d34b0dea86780a31d
provider
NCBI PubMed ESummary
record sha256
1d9c225713390bf5b20e53f3573442285d99ca902e76c4ed085b06fcdbf78d4b
response sha256
11c34185eb9e4ea0d3c4d255d31806495349b0f097d492c4e135946541bf4bb5
retrieved at
2026-09-09T23:47:15.495091+00:00
publication date
display
2016 Apr 2
precision
day
year
2016
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Randomized Controlled Trial
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/26719230/
title
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.

Preserved source evidence · Not medical advice